Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab
In some cases, immune-mediated thrombocytopenia (ITP) is severe, and requires second-line therapies such as splenectomy and/or Rituximab. In most cases Rituximab is beneficial and safe but in some (though rare) it induces significant hypogammaglobulinemia and persistent decreases in the number of B cells. Patients in whom baseline levels of serum IgM or IgG are low become more prone to develop common variable immune deficiency (CVID) especially when more than one cycle of Rituximab is given. In a few case reports, immune-mediated thrombocytopenia was shown to precede the development of CVID. This could possibly develop following a second bout with Rituximab. The assessment of baseline serum immunoglobulins should be routine in all patients with chronic ITP and those who are candidates for Rituximab therapy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Harefuah - 151(2012), 11 vom: 09. Nov., Seite 620-1, 655 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Toubi, Elias [VerfasserIn] |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 15.02.2013 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM224628577 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM224628577 | ||
| 003 | DE-627 | ||
| 005 | 20231224063329.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n0748.xml |
| 035 | |a (DE-627)NLM224628577 | ||
| 035 | |a (NLM)23367731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Toubi, Elias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2013 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In some cases, immune-mediated thrombocytopenia (ITP) is severe, and requires second-line therapies such as splenectomy and/or Rituximab. In most cases Rituximab is beneficial and safe but in some (though rare) it induces significant hypogammaglobulinemia and persistent decreases in the number of B cells. Patients in whom baseline levels of serum IgM or IgG are low become more prone to develop common variable immune deficiency (CVID) especially when more than one cycle of Rituximab is given. In a few case reports, immune-mediated thrombocytopenia was shown to precede the development of CVID. This could possibly develop following a second bout with Rituximab. The assessment of baseline serum immunoglobulins should be routine in all patients with chronic ITP and those who are candidates for Rituximab therapy | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a English Abstract | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 151(2012), 11 vom: 09. Nov., Seite 620-1, 655 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2012 |g number:11 |g day:09 |g month:11 |g pages:620-1, 655 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2012 |e 11 |b 09 |c 11 |h 620-1, 655 | ||